NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Clinical Trials (3)
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
Started Aug 2021
77 enrolled
Vein OcclusionMacular Degeneration Choroidal NeovascularizationMacular Edema+1 more
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Started Oct 2013
57 enrolled
Treatment of Ocular Inflammation Associated With Cataract Surgery
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Started Apr 2013
50 enrolled
CataractRetinal EdemaInflammation
Loss of Exclusivity
LOE Date
Nov 11, 2033
93 months away
Patent Expiry
Nov 11, 2033